ArticleESC heart failure2023
Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF.Redox biology · 2026Article
- Influence of Phenotypes on Short-Term Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction-Insights from a North-Eastern Romanian Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- An integrated Biobank in the Swedish Heart Failure Registry-clinomics, proteomics, transcriptomics and genomics.ESC heart failure · 2026Observational
- Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- Racial and ethnic differences in diagnosis, healthcare utilization and 1-year outcomes for patients with significant tricuspid regurgitation.Journal of comparative effectiveness research · 2026Article
- Healthcare cost and utilization before and after the development of significant tricuspid regurgitation by age, sex and race.Journal of comparative effectiveness research · 2026Article
- Clinical effectiveness of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: nationwide cohort study (REFINE-HFpEF).BMJ medicine · 2026Article
- Empagliflozin-pirfenidone dual therapy improves cardiac function and structure in a preclinical two-hit HFpEF model.Frontiers in pharmacology · 2026Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Predictors of Long-Term Mortality in Medically Treated Patients With Chronic Heart Failure in Kosovo.Reviews in cardiovascular medicine · 2025Article
- Low peak oxygen uptake in relation to total heart volume as an early marker of sub-clinical diastolic dysfunction.European heart journal. Imaging methods and practice · 2025Article
- The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF).ESC heart failure · 2025Article
- Prevalence and Long-Term Prognostic Significance of Advanced Diastolic Dysfunction Among Hospitalized Patients Referred for Echocardiography.Journal of clinical medicine · 2025Article
- Mitochondrial Reactive Oxygen Species Dysregulation in Heart Failure with Preserved Ejection Fraction: A Fraction of the Whole.Antioxidants (Basel, Switzerland) · 2024Review
- Do we really need a heart failure with preserved ejection fraction-specific risk stratification strategy?ESC heart failure · 2024Article
- Anemia and Iron Deficiency Predict All-Cause Mortality in Patients with Heart Failure and Preserved Ejection Fraction: 6-Year Follow-Up Study.Diagnostics (Basel, Switzerland) · 2024Article
- Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery.Acta pharmacologica Sinica · 2024Review
- Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality.ESC heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure (HF) with preserved ejection fraction (HFpEF) is associated with cardiovascular (CV) and non-CV events, but long-term risk is poorly studied. We assessed incidence and predictors of the long-term CV and non-CV events. METHODS AND
resultsPatients presenting with acute HF, EF ≥ 45%, and N-terminal pro-brain natriuretic peptide > 300 ng/L were enrolled in the Karolinska-Rennes study in 2007-11 and were reassessed after 4-8 weeks in a stable state. Long-term follow-up was conducted in 2018. The Fine-Gray sub-distribution hazard regression was used to detect predictors of CV and non-CV deaths, investigated separately from baseline acute presentation (demographic data only) and from the 4-8 week outpatient visit (including echocardiographic data). Of 539 patients enrolled [median age 78 (interquartile range: 72-84) years; 52% female], 397 patients were available for the long-term follow-up. Over a median follow-up time from acute presentation of 5.4 (2.1-7.9) years, 269 (68%) patients died, 128 (47%) from CV and 120 (45%) from non-CV causes. Incidence rates per 1000 patient-years were 62 [95% confidence interval (CI) 52-74] for CV and 58 (95% CI 48-69) for non-CV death. Higher age and coronary artery disease (CAD) were independent predictors of CV death, and anaemia, stroke, kidney disease, and lower body mass index (BMI) and sodium concentrations of non-CV death. From the stable 4-8 week visit, anaemia, CAD, and tricuspid regurgitation (>3.1 m/s) were independent predictors of CV death, and higher age of non-CV death.
conclusionsIn patients with acute decompensated HFpEF, over 5 years of follow-up, nearly two-thirds of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both outcomes. [Correction added on 24 March 2023, after first online publication: In the first sentence of the Conclusions, 'two-thirds' has been inserted before 'of patients died...' in this version.].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.